Company Profile For Speedel Holding AG

Speedel Holding AG, formerly known as Speedel Holding Ltd (Speedel), is a biopharmaceutical company engaged in the research, development and future commercialization of new therapies for cardiovascular and metabolic diseases. The Company focuses particularly on the treatment of hypertension and the research and development of renin inhibitors. Its products include SPP100, a direct renin inhibitor for the treatment of hypertension. The Company’s pipeline covers three different modes of action, and in addition to SPP100, includes SPP635 for the treatment of hypertension in Phase II, SPP1148 and SPP676 renin inhibitors in Phase I and several pre-clinical projects. The products and projects originators are Novartis, Abbott, Roche, Locus and Speedel itself.

BRIEF: For the six months ended 30 June 2008, Speedel Holding AG's revenue increased from SF1M to SF5.7M. Net loss for the period decreased 39% to SF23.4M. Revenue reflects royalty income on global net sales of SPP100 by Novartis and compensation from Novartis for reduced manufacturing costs of SPP100. Lower net loss for the period reflects decreased eternal research and development expenses.